Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report

被引：0
作者：
Salma Machan
Carlos Plaza
Yosmar Pérez-González
Maria Rodriguez-Pinilla
Luis Requena
Raul Cordoba
机构：
[1] Fundación Jiménez Díaz University Hospital,Department of Dermatology
[2] Health Research Institute IIS-FJD,Lymphoma Unit, Department of Hematology
[3] Oncohealth Institute,Department of Pathology
[4] Fundación Jimenez Diaz University Hospital,undefined
[5] Health Research Institute IIS-FJS,undefined
[6] Autonomous University of Madrid,undefined
[7] Fundación Jiménez Díaz University Hospital,undefined
[8] Health Research Institute IIS-FJD,undefined
来源：
Journal of Medical Case Reports | / 14卷
关键词：
Adverse drug event; Cutaneous drug reaction; Case report; Follicular lymphoma; Idelalisib; Rash; Psoriasis-like; Psoriasiform;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [1] Barrientos JC(2016)Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential Onco Targets Ther 9 2945-2953
  • [2] Gopal AK(2014)PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma N Engl J Med 370 1008-1018
  • [3] Kahl BS(2016)Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 27 v83-v90
  • [4] de Vos S(2015)Safety of idelalisib in B-cell malignancies: integrated analysis of eight clinical trials [abstract] J Clin Oncol. 33 1719-1728
  • [5] Wagner-Johnston ND(2017)Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials Drug Des Devel Ther 11 e156-e159
  • [6] Schuster SJ(2017)Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study Haematologica. 102 142-146
  • [7] Jurczak WJ(2017)Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease Clin J Gastroenterol 10 e192-e193
  • [8] Dreyling M.(2018)A slowly developed severe cutaneous adverse reaction to idelalisib J Eur Acad Dermatol Venereol 32 undefined-undefined
  • [9] Ghielmini M.(undefined)undefined undefined undefined undefined-undefined
  • [10] Rule S.(undefined)undefined undefined undefined undefined-undefined
12345